 | |
| Clinical data | |
|---|---|
| Trade names | Tiadipona (ES) |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral (tablets) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Elimination half-life | 2–4 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.123.659 |
| Chemical and physical data | |
| Formula | C17H16N2OS |
| Molar mass | 296.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Bentazepam [1] (also known as Thiadipone, Tiadipona) is a thienodiazepine which is a benzodiazepine analog. [2]
It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Peak plasma rates are achieved in around 2,5 hours after oral administration. [3] The elimination half-life is between approximately 2–4 hours. [2] [4] Bentazepam is effective as an anxiolytic.
A severe benzodiazepine overdose with bentazepam may result in coma and respiratory failure. [5] Adverse effects include dry mouth, somnolence, asthenia, dyspepsia, constipation, nausea [6] and drug-induced lymphocytic colitis has been associated with bentazepam. [7] [8] Severe liver damage and hepatitis has also been associated with bentazepam. [9] [10] [11] Whilst liver failure from bentazepam is considered to be rare, liver function monitoring has been recommended for all patients taking bentazepam. [12]
